WHWei Hou

Wei Hou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wei Hou has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • An Qin

    Department of Orthopaedics, Shanghai Key Laboratory of Orthopaedic Implant, Shanghai Ninth People' s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China

    1 shared publication
  • Hailong Ma

    Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine

    1 shared publication
  • Hang Zhang

    Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedic Surgery, Shanghai Ninth People's Hospital

    1 shared publication
  • Hongtao Xu

    Shanghai Institute for Advanced Immunochemical Studies & School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China

    1 shared publication
  • Jie Li

    ShanghaiTech University

    1 shared publication
  • Peixiang Ma

    Shanghai Key Laboratory of Orthopedic Implants, Department of Orthopedics, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China

    1 shared publication

Latest Publications

  • Open Access

    Discovery of hALPL Agonists for Osteogenesis from A Selenium-containing DNA-encoded Natural Product Library

    by Peixiang Ma, Shuning Zhang, Hang Zhang, Wanting Bi, Shaoneng Hou, Hailong Ma, Shuai Zhao, Jie Li, Tangjun Zhou, Wei Hou, et al.

    Tissue-nonspecific alkaline phosphatase (hALPL) deficiency or dysfunction is a key driver of bone developmental abnormalities. However, no small-molecule agonists are available for the therapeutic target hALPL—particularly its pathogenic mutants. We bridge this gap by developing an antibody maturation-inspired chemical maturation strategy that integrates DNA-encoded library (DEL) selection with parallel synthesis for rapid functional chemical discovery. Using a selenium-containing DNA-encoded natural product library (Se-nDEL), comprising 25900 selenium-containing derivatives and affinity-based selection, we identified hALPL-binding candidates. The candidates were further functionally matured via selenium-nitrogen exchange (SeNEx) chemistry-enabled in situ nanomole-scale parallel synthesis. These efforts culminated in the identification of E7, the first small-molecule hALPL agonist, which directly binds to and activates hALPL, thereby promoting osteogenesis both in vitro and in vivo. Notably, E7 demonstrated the ability to restore the enzymatic activities of seven pathogenic mutations, further highlighting its therapeutic potential. Our work establishes a scalable platform for agonist development, combining DEL-driven hit discovery with parallel synthesis for functional optimization, with broad applicability to challenging targets in bone biology and beyond.